Multivariable Cox regression model with survival curves adjusted for cancer stage. Survival data calculated based on the tumor node metastasis staging system for stage III (A) and stage IV (B). There was a statistically significant reduction in survival in the neurolysis group compared with the control group for stage IV patients (hazard ratio, 1.94 [95% CI, 1.29 to 2.93]; P = 0.001), but there was no difference for stage III patients (hazard ratio, 1.08 [95% CI, 0.59 to 1.97]; P = 0.809). The median survival times for patients with stage III disease were 197.0 and 169.0 days for the neurolysis and control groups, respectively. For patients with stage IV disease, the median survival times were 69.0 and 146.0 days for the neurolysis and control groups, respectively.